Pulmonary surfactant mitigates silver nanoparticle toxicity in human alveolar type-I-like epithelial cells; Colloids and Surfaces B: Biointerfaces; Vol. 145

Opis bibliograficzny
Parent link:Colloids and Surfaces B: Biointerfaces: Scientific Journal
Vol. 145.— 2016.— [P. 167–175]
Korporacja: Национальный исследовательский Томский политехнический университет Физико-технический институт Кафедра теоретической и экспериментальной физики Центр технологий
Kolejni autorzy: Sweeney S. Sinbad, Leo B. F. Bey Fen, Chen S. Shu, Abraham-Thomas N. Nisha, Thorley A. J. Andrew, Gou E. D. Endryu Dzhon, Schwander S. Stephan, Zhang J. J. Junfeng Jim, Shaffer M. S. P. Milo, Chung K. F. Kian Fan, Ryan M. P. Mary, Porter A. E. Alexandra, Tetley T. D. Teresa
Streszczenie:Title screen
Accompanying increased commercial applications and production of silver nanomaterials is an increased probability of human exposure, with inhalation a key route. Nanomaterials that deposit in the pulmonary alveolar region following inhalation will interact firstly with pulmonary surfactant before they interact with the alveolar epithelium. It is therefore critical to understand the effects of human pulmonary surfactant when evaluating the inhalation toxicity of silver nanoparticles. In this study, we evaluated the toxicity of AgNPs on human alveolar type-I-like epithelial (TT1) cells in the absence and presence of Curosurf® (a natural pulmonary surfactant substitute), hypothesising that the pulmonary surfactant would act to modify toxicity. We demonstrated that 20 nm citrate-capped AgNPs induce toxicity in human alveolar type I-like epithelial cells and, in agreement with our hypothesis, that pulmonary surfactant acts to mitigate this toxicity, possibly through reducing AgNP dissolution into cytotoxic Ag+ ions. For example, IL-6 and IL-8 release by TT1 cells significantly increased 10.7- and 35-fold, respectively (P < 0.01), 24 h after treatment with 25 μg/ml AgNPs. In contrast, following pre-incubation of AgNPs with Curosurf®, this effect was almost completely abolished. We further determined that the mechanism of this toxicity is likely associated with Ag+ ion release and lysosomal disruption, but not with increased reactive oxygen species generation. This study provides a critical understanding of the toxicity of AgNPs in target human alveolar type-I-like epithelial cells and the role of pulmonary surfactant in mitigating this toxicity. The observations reported have important implications for the manufacture and application of AgNPs, in particular for applications involving use of aerosolised AgNPs.
Режим доступа: по договору с организацией-держателем ресурса
Język:angielski
Wydane: 2016
Hasła przedmiotowe:
Dostęp online:http://dx.doi.org/10.1016/j.colsurfb.2016.04.040
Format: MixedMaterials Elektroniczne Rozdział
KOHA link:https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=649460

MARC

LEADER 00000naa0a2200000 4500
001 649460
005 20250305144801.0
035 |a (RuTPU)RU\TPU\network\14622 
035 |a RU\TPU\network\7874 
090 |a 649460 
100 |a 20160718d2016 k||y0rusy50 ba 
101 0 |a eng 
135 |a drcn ---uucaa 
181 0 |a i  
182 0 |a b 
200 1 |a Pulmonary surfactant mitigates silver nanoparticle toxicity in human alveolar type-I-like epithelial cells  |f S. Sweeney [et al.] 
203 |a Text  |c electronic 
300 |a Title screen 
320 |a [References: p. 174-175 (44 tit.)] 
330 |a Accompanying increased commercial applications and production of silver nanomaterials is an increased probability of human exposure, with inhalation a key route. Nanomaterials that deposit in the pulmonary alveolar region following inhalation will interact firstly with pulmonary surfactant before they interact with the alveolar epithelium. It is therefore critical to understand the effects of human pulmonary surfactant when evaluating the inhalation toxicity of silver nanoparticles. In this study, we evaluated the toxicity of AgNPs on human alveolar type-I-like epithelial (TT1) cells in the absence and presence of Curosurf® (a natural pulmonary surfactant substitute), hypothesising that the pulmonary surfactant would act to modify toxicity. We demonstrated that 20 nm citrate-capped AgNPs induce toxicity in human alveolar type I-like epithelial cells and, in agreement with our hypothesis, that pulmonary surfactant acts to mitigate this toxicity, possibly through reducing AgNP dissolution into cytotoxic Ag+ ions. For example, IL-6 and IL-8 release by TT1 cells significantly increased 10.7- and 35-fold, respectively (P < 0.01), 24 h after treatment with 25 μg/ml AgNPs. In contrast, following pre-incubation of AgNPs with Curosurf®, this effect was almost completely abolished. We further determined that the mechanism of this toxicity is likely associated with Ag+ ion release and lysosomal disruption, but not with increased reactive oxygen species generation. This study provides a critical understanding of the toxicity of AgNPs in target human alveolar type-I-like epithelial cells and the role of pulmonary surfactant in mitigating this toxicity. The observations reported have important implications for the manufacture and application of AgNPs, in particular for applications involving use of aerosolised AgNPs. 
333 |a Режим доступа: по договору с организацией-держателем ресурса 
461 |t Colloids and Surfaces B: Biointerfaces  |o Scientific Journal 
463 |t Vol. 145  |v [P. 167–175]  |d 2016 
610 1 |a электронный ресурс 
610 1 |a труды учёных ТПУ 
701 1 |a Sweeney  |b S.  |g Sinbad 
701 1 |a Leo  |b B. F.  |g Bey Fen 
701 1 |a Chen  |b S.  |g Shu 
701 1 |a Abraham-Thomas  |b N.  |g Nisha 
701 1 |a Thorley  |b A. J.  |g Andrew 
701 1 |a Gou  |b E. D.  |c biochemist  |c The Head of the Laboratory of Tomsk Polytechnic University, Candidate of philosophical sciences  |f 1964-  |g Endryu Dzhon  |3 (RuTPU)RU\TPU\pers\37014  |9 20029 
701 1 |a Schwander  |b S.  |g Stephan 
701 1 |a Zhang  |b J. J.  |g Junfeng Jim 
701 1 |a Shaffer  |b M. S. P.  |g Milo 
701 1 |a Chung  |b K. F.  |g Kian Fan 
701 1 |a Ryan  |b M. P.  |g Mary 
701 1 |a Porter  |b A. E.  |g Alexandra 
701 1 |a Tetley  |b T. D.  |g Teresa 
712 0 2 |a Национальный исследовательский Томский политехнический университет  |b Физико-технический институт  |b Кафедра теоретической и экспериментальной физики  |b Центр технологий  |3 (RuTPU)RU\TPU\col\20620  |9 27783 
801 2 |a RU  |b 63413507  |c 20170113  |g RCR 
856 4 |u http://dx.doi.org/10.1016/j.colsurfb.2016.04.040 
942 |c CF